COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERINGGlobeNewsWire · 6 days ago
COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERINGGlobeNewsWire · Sep 16, 2026
Brightline Interactive Signs Teaming Agreement with CSCI to Support Unmanned Aircraft and eVTOLs for LIFTOff Louisiana, a Test Site Under the FAA eIPPAccesswire · Aug 26, 2026
COSCIENS Biopharma Inc. Reports Q2 2026 ResultsGlobeNewsWire · Aug 11, 2026COSCIENS Biopharma Inc. is a specialized biopharmaceutical company dedicated to the global development and commercialization of innovative therapeutic and diagnostic products. Its operations extend across Canada, Switzerland, Ireland, Denmark, Germany, the United States, and other international territories. The company's flagship product is Macrilen (macimorelin), an orally administered peptidomimetic ghrelin receptor (GHSR-1a) agonist.